Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723489 · ClinicalTrials.gov registry record · Phase 1
Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis
A Phase 1 study of Atopic Dermatitis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
- 3
- Study locations
NCT00723489 is a Phase 1 study of Atopic Dermatitis that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 82 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00723489, a Phase 1 study of Atopic Dermatitis, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
- 3
- Study locations
Study Summary
The main objective of the Atopic Dermatitis and Vaccinia Immunization Network (ADVN) is to reduce the risk of the fatal reaction, eczema vaccinatum (EV), to the smallpox vaccination in those with atopic dermatitis (AD). Since vaccination with live vaccinia virus (VV) in individuals with AD increases the risk of EV, a yellow fever vaccine was chosen. The purpose of this study is to determine the immune response to a yellow fever vaccine in adults with AD.
Conditions Studied
Interventions
- BIOLOGICAL Live Yellow Fever Vaccine (YFV-17D)
- DRUG YFV-17D Placebo
Study Locations (3)
California
- University of California, San Diego - San Diego
Colorado
- National Jewish Health - Denver
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2008-08 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00723489
The ClinicalTrials.gov registry entry for NCT00723489 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (87% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Live Yellow Fever Vaccine (YFV-17D) is the first listed.
NCT00723489 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Colorado, Oregon.
Frequently Asked Questions
What is clinical trial NCT00723489 about?
NCT00723489 is a clinical study titled "Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis". The main objective of the Atopic Dermatitis and Vaccinia Immunization Network (ADVN) is to reduce the risk of the fatal reaction, eczema vaccinatum (EV), to the smallpox vaccination in those with atopic dermatitis (AD). Since vaccination with live vaccinia virus (VV) in individuals with AD increases...
What is the current status of trial NCT00723489?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2008-08. Estimated completion is 2011-04.
What conditions does trial NCT00723489 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT00723489?
The interventions under investigation include: Live Yellow Fever Vaccine (YFV-17D) (BIOLOGICAL), YFV-17D Placebo (DRUG).
Who is sponsoring clinical trial NCT00723489?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00723489 being conducted?
This trial has 3 study locations across California, Colorado, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 1
-
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
RECRUITING · Phase 1
-
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.